What we do Ind-Swift Laboratories Ltd is a leading Indian pharmaceutical company specializing in formulation manufacturing and finished dosage forms with a strong global export presence. |
Founded in 1,995 |
Market share Prominent player in India and key regulated international markets, with leadership in branded generics and contract manufacturing. |
Problem solved Provides quality pharmaceutical formulations addressing chronic and acute diseases for global healthcare needs. |
Top clients or who we serve Serves pharmaceutical companies, healthcare providers, and patients worldwide; operates in B2B and B2C segments. |
Key management Navrattan Munjal (Chairman & Whole Time Director), Sahil Munjal (Managing Director - Global Operations), Himanshu Jain (Managing Director - Domestic Operations). |
Our journey and innovations From API manufacturing since 1997 to a pure-play formulations firm via merger with Ind-Swift Ltd and strategic divestitures, expanding regulated market approvals and product pipelines. |
Where we operate Operations in India with manufacturing units in Punjab and Jammu; exports to 85+ countries including USA, Europe, Middle East, Africa, and Asia. |
Top products or what we offer Offers finished dosage formulations including ethicals, generics, contract manufacturing (CMO), and own brand products mainly for chronic therapies. |
Top brands Key products: Clarithromycin Granules, Atorvastatin, Fexofenadine, Metformin, Aripiprazole with significant presence in global regulated markets. |
Raw materials needed Pharmaceutical raw materials and active pharmaceutical ingredients for formulation production. |
Raw materials supplier Global and local suppliers aided by import office in China for material sourcing. |
Recurring vs cyclical contribution Revenue is mainly recurring from formulations with some cyclical elements in contract manufacturing and domestic generics. |
Our industry position Strong industry position as a regulated market-focused formulation company with historical leadership in macrolide APIs and expanding global footprint. |
Financial highlights FY25 standalone revenue approx ₹561.7 crore; net profit ₹250.5 crore. Consolidated turnover ₹561.7 crore with continued profitability post business realignment. |
Geographical revenue split Revenue split: Domestic ~28%, Exports ~72%, with major export markets in USA, Europe, Middle East, and Africa. |
Order book Strong order pipeline for contract manufacturing and global formulation exports supported by 1915+ dossiers filed. |
Whats driving growth Growth driven by export expansion, regulatory approvals, own-brand launches, strategic partnerships, and operational efficiencies. |
Our future plans Focus on scaling formulations with new product launches, expanding global market access, and strengthening partnerships like Viatris. |
Our green promise Committed to energy cost reduction via waste heat recovery and maintaining regulatory environmental compliance. |
Our people and values Around 2500 employees; emphasis on health, safety, inclusion and a high-performance culture. |
Key challenges ahead Competition, regulatory changes, raw material price volatility, and integration post-merger. |
Interesting facts Transitioned from API leader to a net debt-free pure-play formulations company through strategic divestment and merger in 2024-25. |
Risks and strategy Mitigates risks via strong compliance, geographic diversification, robust R&D, and customer partnerships; streamlined operations post-merger. |
